Roche (OTCQX:RHHBY) will collaborate with Suzhou, China-based Innovent Biologics (OTCPK:IVBIY)
on the discovery, development and commercialization of bispecific
antibodies and multiple cell therapies for the treatment of blood
cancers and solid tumors.
Under the terms of the partnership, Innovent will
pay Roche an upfront fee, milestones and royalties on net sales in
exchange for non-exclusive access to certain Roche technologies related
to the discovery and development of 2:1 T-cell bispecific antibodies and
a universal CAR-T platform.
Innovent will create, manufacture and
commercialize the products, while Roche will have the option to
in-license each product for development and commercialization ex-China.
If it elects to exercise all of its options, it will pay Innovent $140M
in option exercise payments, up to $1.96B in milestones if all are
successfully developed and commercialized and double-digit-to-mid-teen
royalties on sales of each product.
https://seekingalpha.com/news/3581396-roche-teams-up-innovent-in-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.